Sunshine Biopharma (SBFM) Notes Payables: 2012-2021
Historic Notes Payables for Sunshine Biopharma (SBFM) over the last 7 years, with Dec 2021 value amounting to $1.9 million.
- Sunshine Biopharma's Notes Payables rose 131.58% to $1.9 million in Q4 2021 from the same period last year, while for Dec 2021 it was $1.9 million, marking a year-over-year increase of 131.58%. This contributed to the annual value of $1.9 million for FY2021, which is 131.58% up from last year.
- Latest data reveals that Sunshine Biopharma reported Notes Payables of $1.9 million as of Q4 2021, which was up 475.76% from $330,000 recorded in Q3 2021.
- Sunshine Biopharma's 5-year Notes Payables high stood at $1.9 million for Q4 2021, and its period low was $183,889 during Q1 2017.
- Over the past 3 years, Sunshine Biopharma's median Notes Payables value was $586,307 (recorded in 2019), while the average stood at $685,271.
- Examining YoY changes over the last 5 years, Sunshine Biopharma's Notes Payables showed a top increase of 257.16% in 2017 and a maximum decrease of 74.46% in 2017.
- Quarterly analysis of 5 years shows Sunshine Biopharma's Notes Payables stood at $596,577 in 2017, then declined by 29.65% to $419,663 in 2018, then skyrocketed by 39.71% to $586,307 in 2019, then spiked by 39.94% to $820,454 in 2020, then soared by 131.58% to $1.9 million in 2021.
- Its Notes Payables stands at $1.9 million for Q4 2021, versus $330,000 for Q3 2021 and $330,000 for Q2 2021.